vs
AVANOS MEDICAL, INC.（AVNS）とCSG SYSTEMS INTERNATIONAL INC（CSGS）の財務データ比較。上の社名をクリックして会社を切り替えられます
CSG SYSTEMS INTERNATIONAL INCの直近四半期売上が大きい（$323.1M vs $180.9M、AVANOS MEDICAL, INC.の約1.8倍）。CSG SYSTEMS INTERNATIONAL INCの純利益率が高く（2.2% vs -0.7%、差は2.9%）。CSG SYSTEMS INTERNATIONAL INCの前年同期比売上増加率が高い（2.0% vs 0.7%）。CSG SYSTEMS INTERNATIONAL INCの直近四半期フリーキャッシュフローが多い（$55.8M vs $21.3M）。過去8四半期でCSG SYSTEMS INTERNATIONAL INCの売上複合成長率が高い（4.6% vs 4.4%）
Avanos Medicalは医療テクノロジー企業で、臨床医療機器の開発・製造に注力しており、疼痛管理と慢性ケアの2つのコア事業を展開しています。患者の回復促進や感染予防に取り組みながら、治療におけるオピオイド系薬剤の使用削減を目指しています。
中国南玻集団股フン有限公司は中国最大級の建築用ガラスメーカーで、浮きガラス、建築用ガラス、ディスプレイ用ガラス、自動車用ガラス、コーティングガラス、鏡、カラーフィルターガラス、太陽光発電用ガラス、省エネガラスなど多種多様なガラス製品の製造・販売を手がけています。
AVNS vs CSGS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $180.9M | $323.1M |
| 純利益 | $-1.3M | $7.0M |
| 粗利率 | 47.5% | 50.0% |
| 営業利益率 | 1.4% | 9.0% |
| 純利益率 | -0.7% | 2.2% |
| 売上前年比 | 0.7% | 2.0% |
| 純利益前年比 | 99.7% | -79.7% |
| EPS（希薄化後） | $-0.02 | $0.24 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $180.9M | $323.1M | ||
| Q3 25 | $177.8M | $303.6M | ||
| Q2 25 | $175.0M | $297.1M | ||
| Q1 25 | $167.5M | $299.5M | ||
| Q4 24 | $179.6M | $316.7M | ||
| Q3 24 | $170.4M | $295.1M | ||
| Q2 24 | $171.7M | $290.3M | ||
| Q1 24 | $166.1M | $295.1M |
| Q4 25 | $-1.3M | $7.0M | ||
| Q3 25 | $-1.4M | $20.5M | ||
| Q2 25 | $-76.8M | $12.3M | ||
| Q1 25 | $6.6M | $16.1M | ||
| Q4 24 | $-397.3M | $34.5M | ||
| Q3 24 | $4.3M | $19.1M | ||
| Q2 24 | $1.8M | $13.8M | ||
| Q1 24 | $-900.0K | $19.5M |
| Q4 25 | 47.5% | 50.0% | ||
| Q3 25 | 48.4% | 48.1% | ||
| Q2 25 | 52.6% | 49.5% | ||
| Q1 25 | 53.6% | 48.4% | ||
| Q4 24 | 54.6% | 51.3% | ||
| Q3 24 | 54.5% | 49.4% | ||
| Q2 24 | 55.7% | 47.3% | ||
| Q1 24 | 57.1% | 46.5% |
| Q4 25 | 1.4% | 9.0% | ||
| Q3 25 | 0.1% | 10.0% | ||
| Q2 25 | -42.6% | 10.0% | ||
| Q1 25 | 6.1% | 9.8% | ||
| Q4 24 | -233.0% | 13.4% | ||
| Q3 24 | 7.0% | 10.8% | ||
| Q2 24 | 3.7% | 8.8% | ||
| Q1 24 | 2.4% | 10.8% |
| Q4 25 | -0.7% | 2.2% | ||
| Q3 25 | -0.8% | 6.7% | ||
| Q2 25 | -43.9% | 4.1% | ||
| Q1 25 | 3.9% | 5.4% | ||
| Q4 24 | -221.2% | 10.9% | ||
| Q3 24 | 2.5% | 6.5% | ||
| Q2 24 | 1.0% | 4.8% | ||
| Q1 24 | -0.5% | 6.6% |
| Q4 25 | $-0.02 | $0.24 | ||
| Q3 25 | $-0.03 | $0.73 | ||
| Q2 25 | $-1.66 | $0.44 | ||
| Q1 25 | $0.14 | $0.57 | ||
| Q4 24 | $-8.64 | $1.20 | ||
| Q3 24 | $0.09 | $0.67 | ||
| Q2 24 | $0.04 | $0.48 | ||
| Q1 24 | $-0.02 | $0.68 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $89.8M | $180.0M |
| 総負債低いほど良い | $90.3M | $539.5M |
| 株主資本純資産 | $778.2M | $283.7M |
| 総資産 | $1.1B | $1.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.12× | 1.90× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $89.8M | $180.0M | ||
| Q3 25 | $70.5M | $158.4M | ||
| Q2 25 | $90.3M | $145.9M | ||
| Q1 25 | $97.0M | $136.0M | ||
| Q4 24 | $107.7M | $161.8M | ||
| Q3 24 | $89.0M | $118.4M | ||
| Q2 24 | $92.2M | $110.4M | ||
| Q1 24 | $75.8M | $120.8M |
| Q4 25 | $90.3M | $539.5M | ||
| Q3 25 | $93.4M | $538.6M | ||
| Q2 25 | $95.7M | $537.8M | ||
| Q1 25 | $98.0M | $537.6M | ||
| Q4 24 | $125.3M | $538.5M | ||
| Q3 24 | $152.6M | $539.5M | ||
| Q2 24 | $164.9M | $540.5M | ||
| Q1 24 | $167.2M | $541.5M |
| Q4 25 | $778.2M | $283.7M | ||
| Q3 25 | $778.0M | $289.5M | ||
| Q2 25 | $776.3M | $290.7M | ||
| Q1 25 | $839.4M | $283.1M | ||
| Q4 24 | $828.5M | $282.6M | ||
| Q3 24 | $1.2B | $288.4M | ||
| Q2 24 | $1.2B | $273.3M | ||
| Q1 24 | $1.2B | $269.3M |
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $1.7B | $1.4B | ||
| Q2 24 | $1.7B | $1.4B | ||
| Q1 24 | $1.7B | $1.3B |
| Q4 25 | 0.12× | 1.90× | ||
| Q3 25 | 0.12× | 1.86× | ||
| Q2 25 | 0.12× | 1.85× | ||
| Q1 25 | 0.12× | 1.90× | ||
| Q4 24 | 0.15× | 1.91× | ||
| Q3 24 | 0.12× | 1.87× | ||
| Q2 24 | 0.13× | 1.98× | ||
| Q1 24 | 0.14× | 2.01× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $28.2M | $59.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $21.3M | $55.8M |
| FCFマージンFCF / 売上 | 11.8% | 17.3% |
| 設備投資強度設備投資 / 売上 | 3.8% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | — | 8.46× |
| 直近12ヶ月FCF直近4四半期 | $43.1M | $141.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $28.2M | $59.2M | ||
| Q3 25 | $14.0M | $47.9M | ||
| Q2 25 | $6.8M | $37.3M | ||
| Q1 25 | $25.7M | $11.5M | ||
| Q4 24 | $57.9M | $82.5M | ||
| Q3 24 | $23.0M | $39.5M | ||
| Q2 24 | $27.8M | $43.1M | ||
| Q1 24 | $-8.0M | $-29.4M |
| Q4 25 | $21.3M | $55.8M | ||
| Q3 25 | $7.0M | $43.9M | ||
| Q2 25 | $-4.2M | $34.6M | ||
| Q1 25 | $19.0M | $7.1M | ||
| Q4 24 | $53.1M | $76.6M | ||
| Q3 24 | $20.0M | $32.0M | ||
| Q2 24 | $21.9M | $38.8M | ||
| Q1 24 | $-12.1M | $-34.1M |
| Q4 25 | 11.8% | 17.3% | ||
| Q3 25 | 3.9% | 14.5% | ||
| Q2 25 | -2.4% | 11.6% | ||
| Q1 25 | 11.3% | 2.4% | ||
| Q4 24 | 29.6% | 24.2% | ||
| Q3 24 | 11.7% | 10.8% | ||
| Q2 24 | 12.8% | 13.4% | ||
| Q1 24 | -7.3% | -11.6% |
| Q4 25 | 3.8% | 1.1% | ||
| Q3 25 | 3.9% | 1.3% | ||
| Q2 25 | 6.3% | 0.9% | ||
| Q1 25 | 4.0% | 1.5% | ||
| Q4 24 | 2.7% | 1.9% | ||
| Q3 24 | 1.8% | 2.5% | ||
| Q2 24 | 3.4% | 1.5% | ||
| Q1 24 | 2.5% | 1.6% |
| Q4 25 | — | 8.46× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | 3.04× | ||
| Q1 25 | 3.89× | 0.71× | ||
| Q4 24 | — | 2.39× | ||
| Q3 24 | 5.35× | 2.07× | ||
| Q2 24 | 15.44× | 3.12× | ||
| Q1 24 | — | -1.51× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
